Eli Lilly Acquires Three Vaccine Companies for $3.83 Billion
Eli Lilly announced the acquisition of three vaccine companies in a deal valued at up to $3.83 billion as part of its aggressive strategy into infectious disease prevention. The move is driven by emerging research linking common infections like shingles and Epstein-Barr virus (EBV) to long-term health risks such as dementia, stroke, multiple sclerosis, cancer, and infertility.
Tickers: $LLY
Topics: acquisitions infectious disease research pharmaceuticals vaccines